Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?

Alzheimer's Research and Therapy

Volumn 4, Issue 6, 2012, Pages

  Sacino, Amanda N ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PROTEIN;

ALZHEIMER DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EVIDENCE BASED MEDICINE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUALITY OF LIFE; REVIEW; SYNUCLEINOPATHY;

EID: 84869185275     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt151     Document Type: Review

References (75)

1. Parkinsonism: onset, progression and mortality. Hoehn MM, Yahr MD, Neurology 1967 17 427 442 10.1212/WNL.17.5.427 6067254
2. Parkinson's disease: the clinical picture. Simuni T, Hurtig HI, Neurodegenerative Dementias New York: McGraw-Hill, Clark CM, Trojanoswki JQ, 2000 14 193 203
3. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Damier P, Hirsch EC, Agid Y, Graybiel AM, Brain 1999 122 Pt 8 1437 1448 10430830 (Pubitemid 29374122)
4. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen DA, Pakkenberg H, J Neurol Neurosurg Psychiatry 1991 54 30 33 10.1136/jnnp.54.1.30 2010756
5. Parkinson's disease. First of two parts. Lang AE, Lozano AM, N Engl J Med 1998 339 1044 1053 10.1056/NEJM199810083391506 9761807 (Pubitemid 28457867)
6. Parkinson's disease. Second of two parts. Lang AE, Lozano AM, N Engl J Med 1998 339 1130 1143 10.1056/NEJM199810153391607 9770561 (Pubitemid 28465762)
7. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB):report of the consortium on DLB international workshop. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH, Neurology 1996 47 1113 1124 10.1212/WNL.47.5.1113 8909416 (Pubitemid 26374873)
8. Pathophysiological bases of the non-motor symptoms in Parkinson's disease. Erro ME, Moreno MP, Zandio B, Rev Neurol 2010 50 Suppl 2 7 13 20205146
9. Neuropathology of non-motor features of Parkinson disease. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE, Parkinsonism Relat Disord 2009 15 Suppl 3 1 S5 20882687
10. Staging of brain pathology related to sporadic Parkinson's disease. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E, Neurobiol Aging 2003 24 197 211 10.1016/S0197-4580(02)00065-9 12498954 (Pubitemid 36007810)
11. Pathoanatomy of Parkinson's disease. Braak H, Braak E, J Neurol 2000 247 Suppl 2 I3 10 10991663
12. Alpha-synuclein and neurodegenerative diseases. Goedert M, Nat Rev Neurosci 2001 2 492 501 10.1038/35081564 11433374 (Pubitemid 33676584)
13. Molecular mechanisms of alpha-synuclein neurodegeneration. Waxman EA, Giasson BI, Biochim Biophys Acta 2008 1792 616 624 18955133
14. Alpha-synuclein in Lewy bodies. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M, Nature 1997 388 839 840 10.1038/42166 9278044 (Pubitemid 27377048)
15. Prion-like disorders: blurring the divide between transmissibility and infectivity. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J, J Cell Sci 2010 123 1191 1201 10.1242/jcs.051672 20356930
16. Recent advances in the genetics of Parkinson's disease. Martin I, Dawson VL, Dawson TM, Annu Rev Genomics Hum Genet 2011 12 301 325 10.1146/annurev- genom-082410-101440 21639795
17. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Lesage S, Brice A, Hum Mol Genet 2009 18 48 R59 10.1093/hmg/ddp012 19297401
18. Parkinson's disease: Exit toxins, enter genetics. Westerlund M, Hoffer B, Olson L, Prog Neurobiol 2010 90 146 156 10.1016/j.pneurobio.2009.11.001 19925845
19. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL, Science 1997 276 2045 2047 10.1126/science.276. 5321.2045 9197268 (Pubitemid 27443610)
20. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson's disease. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O, Nat Genet 1998 18 106 108 10.1038/ng0298-106 9462735
21. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, del Ser T, Munoz DG, de Yebenes JG, Ann Neurol 2004 55 164 173 10.1002/ana.10795 14755719 (Pubitemid 38166992)
22. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW, Ann Neurol 2004 55 174 179 10.1002/ana.10846 14755720 (Pubitemid 38166993)
23. alpha-Synuclein locus triplication causes Parkinson's disease. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K, Science 2003 302 841 10.1126/science.1090278 14593171 (Pubitemid 37339619)
24. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Goldberg MS, Lansbury PT Jr, Nat Cell Biol 2000 2 115 E119 10.1038/35017124 10878819
25. Synuclein activates microglia in a model of Parkinson's disease. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ, Neurobiol Aging 2008 29 1690 1701 10.1016/j.neurobiolaging.2007.04.006 17537546
26. Intravesicular localization and exocytosis of alphasynuclein and its aggregates. Lee HJ, Patel S, Lee SJ, J Neurosci 2005 25 6016 6024 10.1523/JNEUROSCI.0692-05.2005 15976091 (Pubitemid 40911433)
27. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D, FASEB J 2003 17 1945 1947 14519670
28. Detection of oligomeric forms of alphasynuclein protein in human plasma as a potential biomarker for Parkinson's disease. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D, FASEB J 2006 20 419 425 10.1096/fj.03-1449com 16507759 (Pubitemid 44933318)
29. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M, Neurosci Lett 2000 287 65 67 10.1016/S0304-3940(00)01153-8 10841992 (Pubitemid 30332379)
30. Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. Emmanouilidou E, Elenis D, Papasilekas T, Stranjalis G, Gerozissis K, Ioannou PC, Vekrellis K, PLoS One 2011 6 22225 10.1371/journal.pone.0022225 21779395
31. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. Ahn KJ, Paik SR, Chung KC, Kim J, J Neurochem 2006 97 265 279 10.1111/j.1471-4159.2006.03731.x 16524375
32. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ, Int J Biochem Cell Biol 2008 40 1835 1849 10.1016/j.biocel.2008.01.017 18291704
33. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ, Proc Natl Acad Sci USA 2009 106 13010 13015 10.1073/pnas.0903691106 19651612
34. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K, J Neurosci 2010 30 6838 6851 10.1523/JNEUROSCI.5699-09.2010 20484626
35. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P, J Clin Invest 2011 121 715 725 10.1172/JCI43366 21245577
36. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ, J Biol Chem 2010 285 9262 9272 10.1074/jbc.M109.081125 20071342
37. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M, J Biol Chem 1999 274 9843 9846 10.1074/jbc.274.14.9843 10092675 (Pubitemid 29180308)
38. alphasynuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL, J Biol Chem 1999 274 19509 19512 10.1074/jbc.274.28. 19509 10391881 (Pubitemid 29327719)
39. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. Waxman EA, Giasson BI, J Neurochem 2010 113 374 388 10.1111/j.1471-4159.2010. 06592.x 20132485
40. Lee Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Proc Natl Acad Sci USA 2009 106 20051 20056 19892735
41. Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative diseases. Nonaka T, Hasegawa, J Biol Chem 2010 285 34885 34898 10.1074/jbc.M110.148460 20805224
42. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM, Neuron 2011 72 57 71 10.1016/j.neuron.2011.08.033 21982369
43. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del TK, Mov Disord 2006 21 2042 2051 10.1002/mds.21065 17078043 (Pubitemid 46140410)
44. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F, Acta Neuropathol 1988 76 217 221 10.1007/BF00687767 2850698
45. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Braak H, de Vos RA, Bohl J, Del TK, Neurosci Lett 2006 396 67 72 10.1016/j.neulet.2005.11.012 16330147 (Pubitemid 43233790)
46. Accumulation of phosphorylated alpha-synuclein in aging human brain. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama B, J Neuropathol Exp Neurol 2003 62 644 654 12834109 (Pubitemid 36682637)
47. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW, Nat Med 2008 14 504 506 10.1038/nm1747 18391962 (Pubitemid 351655212)
48. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P, Nat Med 2008 14 501 503 10.1038/nm1746 18391963 (Pubitemid 351655211)
49. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P, Mov Disord 2010 25 1091 1096 10.1002/mds.23012 20198645
50. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM, J Exp Med 2012 209 975 986 10.1084/jem.20112457 22508839
51. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T, Neurobiol Aging 2012 33 2225 2228 10.1016/j.neurobiolaging.2011.06. 022 21813214
52. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM, Neuron 2002 34 521 533 10.1016/S0896-6273(02)00682-7 12062037 (Pubitemid 34628750)
53. Research in motion: the enigma of Parkinson's disease pathology spread. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T, Nat Rev Neurosci 2008 9 741 745 18769444
54. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. Emmer KL, Waxman EA, Covy JP, Giasson BI, J Biol Chem 2011 286 35104 35118 10.1074/jbc.M111.247965 21846727
55. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O, Nat Med 2008 14 507 509 10.1038/nm1752 18391961 (Pubitemid 351655215)
56. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Jellinger KA, Biochim Biophys Acta 2009 1792 730 740 10.1016/j.bbadis.2008.07.006 18718530
57. A critical evaluation of the Braak staging scheme for Parkinson's disease. Burke RE, Dauer WT, Vonsattel JP, Ann Neurol 2008 64 485 491 10.1002/ana.21541 19067353
58. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, Ahlskog JE, Neurobiol Aging 2011 32 857 863 10.1016/j.neurobiolaging.2009.05.019 19560232
59. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP, Brain 1994 117 Pt 4 835 845 7922469 (Pubitemid 24281844)
60. Multiple system atrophy: a review of 203 pathologically proven cases. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP, Mov Disord 1997 12 133 147 10.1002/mds.870120203 9087971 (Pubitemid 27152018)
61. Consensus statement on the diagnosis of multiple system atrophy. Gilman S, Low PA, Quinn N, Albanese A, Ben Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK, J Neurol Sci 1999 163 94 98 10.1016/S0022-510X(98)00304-9 10223419 (Pubitemid 29155424)
62. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). Papp MI, Kahn JE, Lantos PL, J Neurol Sci 1989 94 79 100 10.1016/0022-510X(89)90219-0 2559165 (Pubitemid 20019446)
63. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VMY, Trojanowski JQ, J Neuropathol Exp Neurol 2000 59 830 841 11005264
64. Mutliple system atrophy. Lantos PL, Brain Pathol 1997 7 1293 1297
65. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Arima K, Murayama S, Mukoyama M, Inose T, Acta Neuropathol (Berl) 1992 83 453 460 10.1007/BF00310020 1320321
66. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VMY, Ann Neurol 1998 44 415 422 10.1002/ana.410440324 9749615 (Pubitemid 28421453)
67. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M, Neurosci Lett 1998 251 205 208 10.1016/S0304-3940(98)00504-7 9726379 (Pubitemid 28381082)
68. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Arima K, Ueda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M, Acta Neuropathol (Berl) 1998 96 439 444 10.1007/s004010050917 (Pubitemid 28474750)
69. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Kato S, Nakamura H, Acta Neuropathol (Berl) 1990 79 584 594 10.1007/BF00294235 (Pubitemid 20170334)
70. Identification of two distinct synucleins from human brain. Jakes R, Spillantini MG, Goedert M, FEBS Lett 1994 345 27 32 10.1016/0014-5793(94)00395-5 8194594 (Pubitemid 24154659)
71. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T, Neuron 1995 14 467 475 10.1016/0896-6273(95)90302-X 7857654
72. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. Maroteaux L, Campanelli JT, Scheller RH, J Neurosci 1988 8 2804 2815 3411354
73. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB, J Neural Transm 2005 112 1613 1624 10.1007/s00702-005- 0378-1 16284907 (Pubitemid 41598967)
74. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. George JM, Jin H, Woods WS, Clayton DF, Neuron 1995 15 361 372 10.1016/0896-6273(95)90040-3 7646890
75. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-Is there a link? Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P, Mol Neurobiol 2012 22544647